Lastly, the immunomodulatory functions of cabozantinib occur through the reduction of MDSCs and the increased activity of circulating cytotoxic NK and CD8+ T cells, acting on both direct and antibody-mediated tumor killing [81]. This evidence concerns the gene CD8A and neoplasm.